The use of social media is now so widespread that professional healthcare organizations have developed guidelines for its use. One of the most recent organizations to create utilization guidelines is the American Congress of Obstetricians and Gynecologists (ACOG), which released its guidelines in April 2015. Other guidelines are available from state medical boards, and the American Medical Association released a statement on the topic in 2010. The American Nurses Association (ANA) released a tool kit, which contain the ANA’s social networking principles, tips for nurses using social media, social media webinar, and a fact sheet.
ANA’s principles include not transmitting or posting identifiable patient information, observing patient-nurse boundaries, and being aware that colleagues and others have the ability to view what is posted. Nurses should utilize privacy settings and ideally, have separate personal and professional online accounts. Nurses also need to bring harmful content to the attention of appropriate individuals or authorities. The ANA notes that misuse of social media can not only damage the individual nurse’s reputation, but may damage the reputation of the nursing profession as well. The toolkit is available at http://www.nursingworld.org/socialnetworkingtoolkit.aspx.
Social Media: Risks and Benefits
The use of social media is now so widespread that professional healthcare organizations have developed guidelines for its use.
The use of social media is now so widespread that professional healthcare organizations have developed guidelines for its use. One of the most recent organizations to create utilization guidelines is the American Congress of Obstetricians and Gynecologists (ACOG), which released its guidelines in April 2015. Other guidelines are available from state medical boards, and the American Medical Association released a statement on the topic in 2010. The American Nurses Association (ANA) released a tool kit, which contain the ANA’s social networking principles, tips for nurses using social media, social media webinar, and a fact sheet.
ANA’s principles include not transmitting or posting identifiable patient information, observing patient-nurse boundaries, and being aware that colleagues and others have the ability to view what is posted. Nurses should utilize privacy settings and ideally, have separate personal and professional online accounts. Nurses also need to bring harmful content to the attention of appropriate individuals or authorities. The ANA notes that misuse of social media can not only damage the individual nurse’s reputation, but may damage the reputation of the nursing profession as well. The toolkit is available at http://www.nursingworld.org/socialnetworkingtoolkit.aspx.
Tovorafenib Gets Accelerated Approval for Pediatric Low-Grade Glioma
April 23rd 2024The FDA approved tovorafenib for certain patients with relapsed or refractory pediatric low-grade glioma.
What New Cancer Drugs Were Approved in 2023?
January 1st 2024In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
December 14th 2023Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.
FDA Requires Boxed Warnings for CAR T-Cell Therapies
April 22nd 2024All patients treated with CAR T-cell products are recommended to be monitored life-long for the risk of secondary malignancy, according to the FDA.
Atezolizumab After Definitive Local Therapy Fails to Improve Survival in HNSCC
April 22nd 2024Patients with head and neck squamous cell carcinoma treated with atezolizumab after definitive local therapy did not see improvements in survival outcomes.
Tovorafenib Gets Accelerated Approval for Pediatric Low-Grade Glioma
April 23rd 2024The FDA approved tovorafenib for certain patients with relapsed or refractory pediatric low-grade glioma.
What New Cancer Drugs Were Approved in 2023?
January 1st 2024In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
December 14th 2023Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.
FDA Requires Boxed Warnings for CAR T-Cell Therapies
April 22nd 2024All patients treated with CAR T-cell products are recommended to be monitored life-long for the risk of secondary malignancy, according to the FDA.
Atezolizumab After Definitive Local Therapy Fails to Improve Survival in HNSCC
April 22nd 2024Patients with head and neck squamous cell carcinoma treated with atezolizumab after definitive local therapy did not see improvements in survival outcomes.
Latest Conference Coverage
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
Less Than Half of Recently Approved Cancer Drugs Show a Clinical Benefit
Cadonilimab Plus Chemo Provides Survival Benefit in Gastric/GEJ Cancer
Lenvatinib Plus Pembrolizumab Improves Survival in Advanced/Recurrent Endometrial Cancer